ANTONIO J GRILLO-LOPEZ
Medical Practice in Rancho Santa Fe, CA
License number
Pennsylvania MD041700E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Rancho Santa Fe, CA 92067
Pennsylvania
Pennsylvania
Professional information
Use Of Chimeric Anti-Cd20 Antibody As In Vitro Or In Vivo Purging Agent In Patients Receiving Bmt Or Pbsc Transplant
US Patent:
2013027, Oct 17, 2013
Filed:
Jun 10, 2013
Appl. No.:
13/914421
Inventors:
Antonio J. GRILLO-LOPEZ - Rancho Santa Fe CA, US
John LEONARD - Carlsbad CA, US
John LEONARD - Carlsbad CA, US
Assignee:
BIOGEN IDEC, INC. - Cambridge MA
International Classification:
A61K 39/395
US Classification:
4241331, 4241731
Abstract:
The use of anti-CD20 antibodies as in vivo purging agents for patients receiving bone marrow or peripheral blood stem cell transplant during treatment of B-cell-related diseases, e.g., B-cell lymphomas or leukemias, is disclosed. Such purging may enhance engraftment and/or prevent disease relapse in such patients.
Intrathecal Administration Of Rituximab For Treatment Of Central Nervous System Lymphomas
US Patent:
2002000, Jan 24, 2002
Filed:
Apr 25, 2001
Appl. No.:
09/840872
Inventors:
Antonio Grillo-Lopez - Rancho Santa Fe CA, US
Assignee:
IDEC Pharmaceuticals Corporation - San Diego CA
International Classification:
A61K051/10, A61K039/395, A61K051/04, A61K031/525, A61K031/475
US Classification:
424/142100, 424/001650, 514/251000, 424/001490, 514/283000
Abstract:
This invention describes methods of using anti-B cell antibodies, preferably anti-CD20 antibodies, and most preferably Rituximab, to treat B cell lymphomas of the brain, especially primary central nervous system lymphomas (PCNSLs), and to prevent meningeal relapse. The antibodies can be administered intrathecally alone, or in combination with other chemotherapeutics, such as methotrexate, or other anti-B cell antibodies to treat PCNSL in both immunocompromised and non-immunocompromised patients. These antibodies can also be used to diagnose patients with CNS lymphoma, especially in immunocompromised patients.
Treatment Of Aggressive Non-Hodgkins Lymphoma With Anti-Cd20 Antibody
US Patent:
8557244, Oct 15, 2013
Filed:
Jul 28, 2000
Appl. No.:
09/628187
Inventors:
Christine White - Rancho Santa Fe CA, US
Antonio Grillo-Lopez - Rancho Santa Fe CA, US
Antonio Grillo-Lopez - Rancho Santa Fe CA, US
Assignee:
Biogen Idec Inc. - Weston MA
International Classification:
A61K 39/395, A61K 31/661, A61K 31/664, A61K 31/704, A61K 31/56, C07K 14/705
US Classification:
4241441, 4241301, 4241331, 4241381, 4241411, 4241431, 4241521, 4241531, 4241551, 4241561, 424801
Abstract:
This invention concerns methods for the treatment of intermediate and high-grade non-Hodgkins lymphomas, comprising the administration of anti-CD20 monoclonal antibodies and fragments thereof. Particular embodiments include the administration of chimeric anti-CD20 antibody, either alone or in combination with radiolabeled antibodies or chemotherapy. The invention is particularly useful for lymphomas characterized by a high number of circulating B cells, possibly bone marrow involvement, bulky disease, or the involvement of extralymphatic organs or sites.
Combination Therapies For B-Cell Lymphomas Comprising Administration Of Anti-Cd20 Antibody
US Patent:
2013027, Oct 17, 2013
Filed:
Apr 23, 2013
Appl. No.:
13/868753
Inventors:
Antonio J. Grillo-Lopez - Rancho Santa Fe CA, US
International Classification:
A61K 39/395
US Classification:
4241331
Abstract:
New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.
Combination Therapies For B-Cell Lynphomas Comprising Administration Of Anti-Cd20 Antibody
US Patent:
2003020, Nov 6, 2003
Filed:
May 19, 2003
Appl. No.:
10/440186
Inventors:
Antonio Grillo-Lopez - Rancho Santa Fe CA, US
Assignee:
IDEC Pharmaceuticals Corporation
International Classification:
A61K039/395
US Classification:
424/144100
Abstract:
New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise in particular administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkins lymphomas.
Treatment Of Multiple Sclerosis
US Patent:
2012020, Aug 9, 2012
Filed:
Apr 18, 2012
Appl. No.:
13/450377
Inventors:
John G. Curd - Hillsborough CA, US
Lori A. Kunkel - Oakland CA, US
Antonio J. Grillo-Lopez - Rancho Santa Fe CA, US
Lori A. Kunkel - Oakland CA, US
Antonio J. Grillo-Lopez - Rancho Santa Fe CA, US
International Classification:
A61K 39/395, A61P 25/00
US Classification:
4241331, 4241731
Abstract:
The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
Treatment Of Autoimmune Diseases
US Patent:
2011000, Jan 13, 2011
Filed:
Sep 20, 2010
Appl. No.:
12/886185
Inventors:
John G. Curd - Hillsborough CA, US
Lori A. Kunkel - Oakland CA, US
Antonio J. Grillo-Lopez - Rancho Santa Fe CA, US
Lori A. Kunkel - Oakland CA, US
Antonio J. Grillo-Lopez - Rancho Santa Fe CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 39/395, A61P 37/00
US Classification:
4241331, 4241731
Abstract:
The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
Treatment Of Multiple Sclerosis
US Patent:
2013008, Apr 4, 2013
Filed:
Nov 20, 2012
Appl. No.:
13/682544
Inventors:
Lori A. Kunkel - Monrovia CA, US
Antonio J. Grillo-Lopez - Rancho Santa Fe CA, US
Antonio J. Grillo-Lopez - Rancho Santa Fe CA, US
Assignee:
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 39/395
US Classification:
4241331, 4241731
Abstract:
The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
Treatment Of Chronic Lymphocytic Leukemia Using Anti-Cd20 Antibodies
US Patent:
8206711, Jun 26, 2012
Filed:
Dec 2, 2009
Appl. No.:
12/629472
Inventors:
Christine A. White - Rancho Santa Fe CA, US
Antonio J. Grillo-Lopez - Rancho Santa Fe CA, US
John G. Curd - Hillsborough CA, US
Susan Desmond-Hellmann - Alamo CA, US
Antonio J. Grillo-Lopez - Rancho Santa Fe CA, US
John G. Curd - Hillsborough CA, US
Susan Desmond-Hellmann - Alamo CA, US
Assignee:
Biogen Idec Inc. - Cambridge MA
Genentech, Inc. - South San Francisco CA
Genentech, Inc. - South San Francisco CA
International Classification:
A61K 39/395, A61K 51/00
US Classification:
4241381, 424 149, 4241331, 4241431, 4241441, 4241531, 4241561, 4241741, 530350, 5303871, 5303873, 5303877, 5303881, 5303882, 53038873, 5303888, 53038885, 5303913
Abstract:
Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.
Treatment Of Multiple Sclerosis
US Patent:
2013027, Oct 17, 2013
Filed:
Jun 11, 2013
Appl. No.:
13/915447
Inventors:
Antonio J. Grillo-Lopez - Rancho Santa Fe CA, US
International Classification:
A61K 39/395
US Classification:
4241331, 4241731
Abstract:
The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.